What blood tests to get, situation by situation

There is no single "complete" blood panel. US screening guidance is built test by test, each one justified by evidence that finding something early changes what happens next. That is why the official list is short, and why commercial panels with 80 markers are mostly measuring things no guideline asks for. This page starts with what the guidelines say for an ordinary adult, then works through four common situations where the list grows.

The routine adult checkup

These are the blood tests with a published recommendation behind them for adults without symptoms.

Two things are notable by their absence. The US Preventive Services Task Force gives vitamin D screening in healthy adults an "I" statement, meaning the evidence is insufficient to recommend for or against it, and the Endocrine Society's 2024 guideline advises against routine testing. And there is no USPSTF recommendation for a routine complete blood count or metabolic panel in adults without symptoms. Both are often ordered anyway, and both are useful as a baseline, but that is a clinical choice rather than a screening rule.

The lipid result feeds a risk calculation. The USPSTF recommends a statin for adults 40 to 75 with at least one risk factor (high cholesterol, diabetes, high blood pressure or smoking) and a 10-year cardiovascular risk of 10 percent or more. The lipid panel guide explains what each number on that report is.

On a GLP-1 receptor agonist

The Wegovy and Zepbound labels do not set a fixed monitoring panel for weight management. Prescribers usually draw a baseline before the first dose: HbA1c and fasting glucose to establish diabetes status, a lipid panel, creatinine and eGFR, and ALT and AST. The labels warn of kidney injury from dehydration after vomiting or diarrhoea, which is why kidney function matters more than usual. For people with diabetes, the ADA's 2026 Standards recommend assessing glycaemic status at least twice a year when at goal and more often, such as every three months, after a treatment change. Starting a GLP-1 is a treatment change. The GLP-1 blood work page has the trial numbers for what moves and by how much.

Before starting a research peptide

For compounds that are not approved drugs there is no label and no monitoring guideline. What people track is borrowed from general screening plus what the published studies show a compound class does. The defensible core is a baseline before anything starts: a complete blood count, a comprehensive metabolic panel (kidney and liver function, glucose, electrolytes), a lipid panel and HbA1c. People using compounds studied for effects on IGF-1 usually add it, because IGF-1 is the marker those studies measured, and they often add fasting glucose and fasting insulin because some of the same compounds affect glucose handling. The peptide blood testing page covers the evidence and its limits. The main thing a baseline buys you is something to compare against later. A single value drawn three months in, with nothing before it, says very little.

Training hard

Hard training changes blood results in ways that look like disease. In a 2008 study in the British Journal of Clinical Pharmacology, 15 healthy men who were not used to weightlifting did one hour of it. AST, ALT, creatine kinase, LD and myoglobin rose significantly and stayed raised for at least seven days, while GGT, ALP and bilirubin stayed normal. The pattern points to muscle, not liver. Creatinine also comes from muscle, so someone with a lot of muscle, or taking creatine, can show an eGFR that looks lower than their kidneys deserve. KDIGO's 2024 guideline suggests adding cystatin C when creatinine-based eGFR may be inaccurate. hs-CRP spikes after injury and very hard sessions too. The practical rule: no hard session for a few days before a draw, and tell whoever reads the result how you train.

Over 40

Forty is where several guidelines start to bite. The USPSTF statin recommendation applies from 40, and its risk calculation needs a recent lipid panel. Diabetes screening has already started at 35. If Lp(a) has never been measured, this is a sensible time, since it is mostly inherited and one result is enough for most people; see the Lp(a) page. Some clinicians add ApoB when triglycerides are high or LDL is low, which is where the 2019 European guideline says ApoB may be preferred. hs-CRP is listed as a risk-enhancing factor in the 2018 ACC/AHA cholesterol guideline at 2 mg/L or more, which makes it useful for borderline cases rather than as a routine screen.

What not to add

Every extra marker raises the chance of a flag that means nothing. Reference intervals are conventionally built from the central 95 percent of healthy people, so 5 percent of healthy results fall outside them by design. On a 40-marker panel, at least one flag is the expected outcome for a healthy person, not a surprise. The lab report guide explains why. Before adding a test, it is worth asking what you would do differently with each possible result. If the answer is nothing, the test is curiosity, and curiosity has a cost in follow-up worry and repeat draws.

How the rest of this section fits

Once you know which tests, the practical questions are how often, whether to fast, how to order them, and how big a change has to be before it means anything. The panel guides cover the CMP, CBC, lipid panel, metabolic markers and inflammatory markers. All of it is collected at bloodwork guides.

Keeping it in one place

In Peptide AI, a lab PDF goes in through bloodwork tracking, and each marker sits on the same timeline as the dose log, weight and training. The baseline you draw before anything starts becomes the first point on every line. Your prescriber still decides what to test and what a result means.